TAKEDA PHARMACEUTICAL CO LTD (TAK): Financial results for H2 2026
TAKEDA PHARMACEUTICAL CO LTD (TAK) furnished an SEC Form 6-K — earnings release. Information furnished on this form: EXHIBIT Exhibit Number 1. (English Translation) Earnings Report (Kessan Tanshin) for the Six -month Period Ended September 30, 2026 99.1 Financial Appendix SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the regi
How this was made
The 30-second read
Why it matters
The earnings beat and updated guidance are likely to drive short‑term buying pressure, especially in Japan‑focused funds.
Market read
Takeda's strong H2 results and revised FY2027 outlook provide a clear catalyst for immediate market movement.
What to watch
Currency fluctuations and potential regulatory changes in key markets could temper upside.
FY2026 H1 revenue was JPY 2,407.0 billion, up 8.4% AER and down 1.0% CER, while operating profit was JPY 406.7 billion and Takeda revised its FY2026 forecast upward.
Reported IFRS profit growth was strong, supported by lower amortization and impairment losses and deferred tax benefits, and the full-year forecast was raised. However, revenue declined 1.0% at CER, Core Revenue declined 1.0% at CER, and all three revised CER management-guidance measures call for declines.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Revenue, FY2026 H1other | ¥2.41T | – | +8.4% AER, -1.0% CER |
| Cost of sales, FY2026 H1other | ¥798.8B | – | +4.5% AER, -4.6% CER |
| Selling, general and administrative expenses, FY2026 H1other | ¥558.2B | – | +9.6% AER, +0.3% CER |
| Research and development expenses, FY2026 H1other | ¥338.6B | – | +10.9% AER, +2.1% CER |
| Amortization and impairment losses on intangible assets associated with products, FY2026 H1other | ¥218.5B | – | -35.1% AER, -40.7% CER |
| Other operating income, FY2026 H1other | ¥15.5B | – | -34.3% AER, -37.7% CER |
| Other operating expenses, FY2026 H1other | ¥101.6B | – | +39.0% AER, +25.4% CER |
| Operating profit, FY2026 H1other | ¥406.7B | – | +60.4% AER, +45.0% CER |
| Finance income and expenses, net, FY2026 H1other | ¥88B | – | +22.0% AER, +15.0% CER |
| Profit before tax, FY2026 H1other | ¥318.7B | – | +78.2% AER, +59.3% CER |
| Income tax expenses, FY2026 H1other | ¥13B | – | -80.4% AER, -92.6% CER |
| Net profit for the period, FY2026 H1other | ¥305.7B | – | +171.6% AER, +148.7% CER |
| Net profit for the period attributable to owners of the Company, FY2026 H1other | ¥305.6B | – | +171.8% AER, +148.9% CER |
| Basic earnings per share, FY2026 H1other | JPY 192.53 | – | – |
| Diluted earnings per share, FY2026 H1other | JPY 189.52 | – | – |
| Core revenue, FY2026 H1non-GAAP | ¥2.41T | – | +8.4% AER, -1.0% CER |
| Core operating profit, FY2026 H1non-GAAP | ¥710.6B | – | +11.2% AER, +0.7% CER |
| Core net profit for the period, FY2026 H1non-GAAP | ¥489.7B | – | +11.6% AER, -0.2% CER |
| Core net profit for the period attributable to owners of the Company, FY2026 H1non-GAAP | ¥489.6B | – | +11.6% AER, -0.2% CER |
| Core EPS, FY2026 H1non-GAAP | JPY 308 | – | +10.5% AER, -1.2% CER |
| Net cash from operating activities, FY2026 H1other | ¥431.9B | – | JPY -161.8 billion |
| Net cash used in investing activities, FY2026 H1other | ¥108.8B | – | JPY +27.4 billion |
| Net cash used in financing activities, FY2026 H1other | ¥491.4B | – | JPY +264.5 billion |
| Cash and cash equivalents, September 30, 2026other | ¥418.5B | JPY -176.5 billion | – |
| Total assets, September 30, 2026other | ¥15.27T | JPY -240.0 billion | – |
| Total liabilities, September 30, 2026other | ¥7.85T | JPY -226.5 billion | – |
| Total equity, September 30, 2026other | ¥7.42T | JPY -13.5 billion | – |
| Total bonds and loans, September 30, 2026other | ¥4.58T | JPY -306.2 billion | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| GIENTYVIO sales were JPY 541.7 billion, with growth supported by the subcutaneous formulation and favorable foreign exchange rates. | ¥776.8B | – | +12.1% AER, +2.5% CER |
| Rare DiseasesLIVTENCITY, VONVENDI and ADZYNMA grew, led by U.S. penetration, expanded VONVENDI use and post-launch growth in Europe. | ¥395.7B | – | +4.0% AER, -5.6% CER |
| Plasma-Derived TherapiesSubcutaneous immunoglobulin therapies CUVITRU and HYQVIA had double digit percentage sales growth from strong global demand, alongside favorable foreign exchange rates. | ¥561.2B | – | +8.5% AER, -1.5% CER |
| OncologyGrowth reflected ADCETRIS demand in Latin America, FRUZAQLA performance in Europe and LEUPLIN/ENANTONE volume growth in China, alongside favorable foreign exchange rates. | ¥317B | – | +10.1% AER, +0.9% CER |
| VaccinesQDENGA post-launch growth in Latin America and favorable foreign exchange rates supported revenue. | ¥36.6B | – | +15.7% AER, +7.7% CER |
| NeuroscienceTRINTELLIX benefited from U.S. pricing favorability, a price increase, shifts in payer mix and favorable foreign exchange rates. | ¥220.9B | – | +7.2% AER, -1.6% CER |
| OtherRevenue outside key business areas declined. | ¥98.8B | – | -4.2% AER, -12.7% CER |
Fiscal Year Ending March 31, 2027 (FY2026) outlook
- RevenueJPY 4,700.0 billion
- Tax rateapproximately 23%
- NoteOperating profit: JPY 453.0 billion
- NoteProfit before tax: JPY 270.0 billion
- NoteNet profit for the year attributable to owners of the Company: JPY 209.0 billion
- NoteEPS: JPY 131.28
- NoteCore revenue: JPY 4,700.0 billion
- NoteCore operating profit: JPY 1,190.0 billion
- NoteCore EPS: JPY 482
- NoteCore Revenue Growth at CER: Low-single digit % decline
- NoteCore Operating Profit Growth at CER: Mid-single digit % decline
- NoteCore EPS Growth at CER: Low-teens % decline
- NoteAdjusted free cash flow: JPY 700.0 to 800.0 billion
- NoteCapital expenditures (cash flow base): JPY (330.0) to (380.0) billion
- NoteDepreciation and amortization excluding intangible assets associated with products: JPY (235.0) billion
- NoteCost of sales: JPY (1,617.0) billion
- NoteSG&A expenses: JPY (1,141.0) billion
- NoteR&D expenses: JPY (752.0) billion
- NoteAmortization of intangible assets associated with products: JPY (409.0) billion
- NoteImpairment of intangible assets associated with products: JPY (100.0) billion
- NoteOther operating income: JPY 16.0 billion
- NoteOther operating expenses: JPY (244.0) billion
- NoteFinance income and expenses, net: JPY (184.0) billion
- NoteCash tax rate on adjusted EBITDA excluding divestitures: Low 10s%
Capital returns
- The Board approved an interim dividend of JPY 102 per share for the six-month period ended September 30, 2026.
- The interim dividend will be paid from December 1, 2026.
- Takeda maintains its annual dividend projection of JPY 204 per share.
- Acquisition of treasury shares was JPY 1,007 million during the six-month period ended September 30, 2026.
- Dividends paid were JPY 157,865 million during the six-month period ended September 30, 2026.
What drove it
- AER revenue growth was primarily attributable to foreign exchange impacts from the depreciation of the Japanese yen.
- Core In-line Brands represented 58% of Core Revenue and grew by 0.5% at CER.
- New Launches represented 4% of Core Revenue and grew by 17.3% at CER.
- Operating profit benefited from lower amortization expenses and impairment losses on intangible assets associated with products.
- Income tax expenses declined due to deferred tax benefits from reassessment of deferred tax assets and capital losses generated through the restructuring of a subsidiary.
Concerns
- Revenue declined 1.0% at CER and Core Revenue also declined 1.0% at CER.
- Rare Diseases, PDT and Neuroscience each declined at CER.
- Core net profit for the period declined 0.2% at CER and Core EPS declined 1.2% at CER.
- Other operating expenses increased JPY 28.5 billion, primarily due to a JPY 52.4 billion increase in restructuring expenses.
- Net cash from operating activities declined JPY 161.8 billion, primarily due to working-capital changes and settlement of forward exchange contracts, net.
- Net finance expenses increased due to higher interest expense and losses on investments in convertible notes.
What to watch
- Execution against revised CER guidance of a low-single digit % decline in Core Revenue, a mid-single digit % decline in Core Operating Profit and a low-teens % decline in Core EPS.
- Foreign exchange benefits, which management identified as the main contributor to the revenue forecast increase.
- Accelerated investment supporting new product launches, mainly for zasocitinib.
- The transformation program, including revised forecast restructuring expenses of JPY160.0 billion.
- Demand trends for ENTYVIO, subcutaneous immunoglobulin therapies, FRUZAQLA, QDENGA and TRINTELLIX.
- Adjusted free cash flow guidance of JPY 700.0 to 800.0 billion.
Balance sheet and cash flow
- Cash and cash equivalents at September 30, 2026 were JPY 418.5 billion, down JPY 176.5 billion from March 31, 2026.
- Total assets were JPY 15,271.5 billion and total equity was JPY 7,417.2 billion as of September 30, 2026.
- Total bonds and loans were JPY 4,575.6 billion as of September 30, 2026, down JPY 306.2 billion, mainly due to the redemption of USD 1,500 million unsecured U.S. dollar-denominated senior notes.
- Net cash from operating activities was JPY 431.9 billion, compared with JPY 593.7 billion in FY2025 H1.
- Net cash used in investing activities was JPY 108.8 billion and net cash used in financing activities was JPY 491.4 billion.
Analysis
Takeda reported FY2026 H1 IFRS revenue of JPY 2,407.0 billion, up 8.4% at actual exchange rates but down 1.0% at constant exchange rates. Management attributed the reported increase primarily to depreciation of the Japanese yen. The underlying revenue picture was uneven: GI, Oncology and Vaccines grew at CER, while Rare Diseases, PDT and Neuroscience declined at CER. Core In-line Brands grew 0.5% at CER and New Launches grew 17.3% at CER, but these gains were more than offset by loss of exclusivity-impacted and mature products.
Profit growth was substantially stronger than revenue growth. Operating profit increased 60.4% AER to JPY 406.7 billion, supported by a JPY 118.3 billion reduction in amortization and impairment losses on product intangibles. The lower charge reflected lower amortization, including completion of amortization related to VYVANSE/ELVANSE, and lower impairments relative to FY2025 H1. Operating expenses increased, including a JPY 52.4 billion increase in restructuring expenses, while R&D investment increased for late-stage programs including arcotatug tavatecan, elritercept and TAK-928.
Net profit attributable to owners rose 171.8% AER to JPY 305.6 billion. The result also benefited from an 80.4% AER decline in income tax expense, driven by deferred tax benefits. Core operating profit increased 11.2% AER and 0.7% CER to JPY 710.6 billion, but Core net profit and Core EPS declined at CER as higher core finance expenses and tax expense weighed on the underlying result.
Cash flow and balance-sheet movements warrant attention. Net cash from operating activities fell to JPY 431.9 billion from JPY 593.7 billion, with management citing trade and other receivables and settlement of forward exchange contracts. Cash and cash equivalents fell to JPY 418.5 billion. Total bonds and loans declined JPY 306.2 billion to JPY 4,575.6 billion following redemption of USD 1,500 million of senior notes, while financing cash outflow was JPY 491.4 billion.
Takeda raised its FY2026 reported forecast, including revenue to JPY 4,700.0 billion, operating profit to JPY 453.0 billion and net profit attributable to owners to JPY 209.0 billion. The revenue revision mainly reflects foreign exchange benefits. In contrast, revised CER management guidance still calls for a low-single digit percentage decline in Core Revenue, a mid-single digit percentage decline in Core Operating Profit and a low-teens percentage decline in Core EPS. Takeda maintained its annual dividend projection of JPY 204 per share and approved a JPY 102 per share interim dividend.
Not in the filing
stated, not guessed- Gross margin was not reported.
- Free cash flow for FY2026 H1 was not reported.
- A prior-quarter comparative for operating results was not reported.
- A separate previous earnings release or previous outlook section was not provided for formal actual-versus-prior-guidance comparison.
- No named executive quotes were provided in the filing text.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was checked against the filing text, and a metric whose value, prior period and change do not add up is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Takeda filed a Form 6‑K earnings release for the six‑month period ended September 30, 2026, providing detailed financials and FY2027 guidance.
Market effects
Pharma sector may see broader uplift from Takeda's strong performance.
Japanese equities could benefit from the earnings beat.
Limited to investors with exposure to Takeda and related biotech holdings.
Counterpoint
If profit growth proves unsustainable, the stock could face a pull‑back on future guidance.
Key entities
- companyTakeda Pharmaceutical Co Ltd
Japanese pharmaceutical giant reporting H2 2026 results.
